Eli Lilly and Company $LLY Stock Holdings Lifted by Woodline Partners LP

Key Points

• Woodline Partners LP has increased its stake in Eli Lilly and Company by 54.5%, now holding 157,297 shares valued at approximately $129.9 million, making it the firm's 10th largest holding.
• Eli Lilly reported a quarterly earnings of $6.31 per share, surpassing analysts' expectations, with revenue of $15.56 billion, a 37.6% increase year-over-year.
• The company announced a quarterly dividend of $1.50 per share, which reflects a 0.8% dividend yield and a payout ratio of 39.22%.

Woodline Partners LP grew its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 54.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 157,297 shares of the company's stock after acquiring an additional 55,488 shares during the quarter. Eli Lilly and Company comprises approximately 0.8% of Woodline Partners LP's investment portfolio, making the stock its 10th largest holding. Woodline Partners LP's holdings in Eli Lilly and Company were worth $129,913,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Zurich Insurance Group Ltd FI raised its holdings in shares of Eli Lilly and Company by 9.6% in the first quarter. Zurich Insurance Group Ltd FI now owns 225,533 shares of the company's stock worth $186,270,000 after buying an additional 19,832 shares during the last quarter. McIlrath & Eck LLC increased its position in shares of Eli Lilly and Company by 16.3% in the 1st quarter. McIlrath & Eck LLC now owns 722 shares of the company's stock valued at $597,000 after acquiring an additional 101 shares during the period. Logan Capital Management Inc. raised its stake in Eli Lilly and Company by 2.2% in the 1st quarter. Logan Capital Management Inc. now owns 32,912 shares of the company's stock worth $27,182,000 after acquiring an additional 718 shares during the last quarter. Northeast Financial Consultants Inc lifted its position in Eli Lilly and Company by 6.0% during the 1st quarter. Northeast Financial Consultants Inc now owns 10,557 shares of the company's stock worth $8,719,000 after acquiring an additional 601 shares during the period. Finally, Peloton Wealth Strategists lifted its position in Eli Lilly and Company by 4.1% during the 1st quarter. Peloton Wealth Strategists now owns 1,111 shares of the company's stock worth $918,000 after acquiring an additional 44 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

LLY opened at $738.58 on Tuesday. The firm has a fifty day moving average price of $743.02 and a 200 day moving average price of $779.63. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $942.35. The stock has a market cap of $699.04 billion, a P/E ratio of 48.27, a P/E/G ratio of 1.01 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the previous year, the company earned $3.92 earnings per share. The firm's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Insider Transactions at Eli Lilly and Company

In related news, CEO David A. Ricks bought 1,632 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 in the last ninety days. Company insiders own 0.13% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Leerink Partners reissued a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Morgan Stanley restated an "overweight" rating and set a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 30th. Finally, Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $950.17.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.